SG11201809845TA - Benzodiazepine product with activity on the central nervous and vascular systems - Google Patents

Benzodiazepine product with activity on the central nervous and vascular systems

Info

Publication number
SG11201809845TA
SG11201809845TA SG11201809845TA SG11201809845TA SG11201809845TA SG 11201809845T A SG11201809845T A SG 11201809845TA SG 11201809845T A SG11201809845T A SG 11201809845TA SG 11201809845T A SG11201809845T A SG 11201809845TA SG 11201809845T A SG11201809845T A SG 11201809845TA
Authority
SG
Singapore
Prior art keywords
central nervous
vascular systems
activity
benzodiazepine
product
Prior art date
Application number
SG11201809845TA
Inventor
Figueredo Yanier Núñez
Guerra Maylin Wong
Fonseca Luis Arturo Fonseca
Suárez Bárbara Beatriz Garrido
Sánchez Jeney Ramírez
Andreu Gilberto Lázaro Pardo
Reyes Yamila Verdecia
Rodríguez Estael Ochoa
Fernández Pedro Gilberto Bárzaga
Alfonso Nicté González
Hernández René Delgado
Yaquis Saúl Alejandro Padrón
Original Assignee
Univ La Habana
Centro De Investig Y Desarrollo De Medicamentos Cidem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ La Habana, Centro De Investig Y Desarrollo De Medicamentos Cidem filed Critical Univ La Habana
Publication of SG11201809845TA publication Critical patent/SG11201809845TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

BENZODIAZEPINE PRODUCT WITH ACTIVITY ON THE CENTRAL NERVOUS AND VASCULAR SYSTEMS The invention relates to a compound of formula III, the derivatives thereof, and pharmaceutical compositions containing same for the treatment of diseases of the central nervous and vascular systems, particularly neurodegenerative disorders with cognitive deterioration, diseases associated with oxidative stress, diseases associated with mitochondrial dysfunction, Parkinson's disease and neuropathic pain, as well as the pathological processes associated with aging. [Figure 2]
SG11201809845TA 2016-05-04 2017-05-03 Benzodiazepine product with activity on the central nervous and vascular systems SG11201809845TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CUP2016000058A CU20160058A7 (en) 2016-05-04 2016-05-04 DERIVED FROM BENZODIAZEPINA WITH ACTIVITY ON THE CENTRAL AND VASCULAR NERVOUS SYSTEM
PCT/CU2017/050002 WO2017190713A1 (en) 2016-05-04 2017-05-03 Benzodiazepine derivative with activity on the central nervous and vascular systems

Publications (1)

Publication Number Publication Date
SG11201809845TA true SG11201809845TA (en) 2018-12-28

Family

ID=59215419

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809845TA SG11201809845TA (en) 2016-05-04 2017-05-03 Benzodiazepine product with activity on the central nervous and vascular systems

Country Status (20)

Country Link
US (1) US11098039B2 (en)
EP (1) EP3470414B1 (en)
JP (1) JP7078959B2 (en)
KR (1) KR102428383B1 (en)
CN (1) CN110114356B (en)
AR (1) AR108369A1 (en)
AU (1) AU2017259748B2 (en)
BR (1) BR112018072588B1 (en)
CA (1) CA3023105C (en)
CL (1) CL2018003113A1 (en)
CU (1) CU20160058A7 (en)
DK (1) DK3470414T3 (en)
EA (1) EA201892461A1 (en)
ES (1) ES2902992T3 (en)
MX (1) MX2018013405A (en)
NZ (1) NZ748959A (en)
SG (1) SG11201809845TA (en)
SI (1) SI3470414T1 (en)
WO (1) WO2017190713A1 (en)
ZA (1) ZA201808162B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20190114A7 (en) * 2019-12-26 2021-08-06 Centro De Investig Y Desarrollo De Medicamentos Cidem COMBINATION TO SIMULTANEOUSLY INCREASE THE ANALGESIC EFFECTIVENESS OF MORPHINE AND REDUCE ITS PHYSICAL DEPENDENCE
BR112022012699A2 (en) * 2019-12-26 2022-09-06 Centro De Investig Y Desarrollo De Medicamentos Cidem USE OF A BENZODIAZEPINE DERIVATIVE AND METHOD OF TREATMENT OF TRAUMATIC BRAIN INJURY

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009137462A2 (en) * 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Methods for treating cognitive disorders using inhibitors of histone deacetylase
CU20090172A7 (en) * 2009-10-09 2011-10-05 Ct De Investigación Y Desarrollo De Medicamentos TRICYCLIC AND TETRACYCLIC SYSTEMS WITH ACTIVITY ON THE CENTRAL AND VASCULAR NERVOUS SYSTEM
CU24576B1 (en) 2016-05-04 2022-02-04 Centro De Investig Y Desarrollo De Medicamentos Cidem PHENOLIC COMPOUND AND COMBINATION THEREOF WITH A BENZODIAZEPINE FUSED TO 1,4-DIHYDROPYRIDINE FOR THE TREATMENT OF DISORDERS OF THE CENTRAL AND VASCULAR NERVOUS SYSTEM

Also Published As

Publication number Publication date
CL2018003113A1 (en) 2019-04-12
NZ748959A (en) 2024-02-23
BR112018072588A2 (en) 2019-02-19
ZA201808162B (en) 2021-08-25
AU2017259748A1 (en) 2018-12-20
ES2902992T3 (en) 2022-03-30
BR112018072588B1 (en) 2024-02-20
WO2017190713A1 (en) 2017-11-09
US20190270738A1 (en) 2019-09-05
EP3470414A1 (en) 2019-04-17
EA201892461A1 (en) 2019-04-30
AR108369A1 (en) 2018-08-15
AU2017259748B2 (en) 2021-08-05
CN110114356B (en) 2021-09-24
SI3470414T1 (en) 2022-03-31
KR102428383B1 (en) 2022-08-02
EP3470414B1 (en) 2021-10-13
DK3470414T3 (en) 2022-01-17
KR20210025137A (en) 2021-03-09
JP2019519600A (en) 2019-07-11
CN110114356A (en) 2019-08-09
CA3023105A1 (en) 2017-11-09
MX2018013405A (en) 2019-08-16
CA3023105C (en) 2023-07-18
US11098039B2 (en) 2021-08-24
JP7078959B2 (en) 2022-06-01
CU20160058A7 (en) 2017-12-08

Similar Documents

Publication Publication Date Title
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
PH12017502228A1 (en) Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
WO2017189823A3 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
EP4010072A4 (en) Treatment of central nervous system disorders
GEP20227446B (en) New catecholamine prodrugs for use in treatment of parkinson's disease
ECSP19048477A (en) BICYCLE INHIBITORS [1.1.1] DUAL LEUCINE ZIPPER KINASE PENTANE (DLK) FOR THE TREATMENT OF DISEASES
WO2012106343A3 (en) Hdac inhibitors and therapeutic methods using the same
MX2020007318A (en) Heterocyclic compound.
WO2019226213A3 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2019002444A (en) Inhibitors of dual leucine ziper (dlk) kinase for the treatment of disease.
WO2018023072A3 (en) Compounds and compositions and uses thereof
PH12017500913A1 (en) Substituted bridged urea analogs as sirtuin modulators
MX2017008083A (en) 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-ami ne compound inhibitors of beta-secretase.
EP3700525A4 (en) Enhanced delivery of antioxidants for treatment of central nervous system disorders involving oxidative stress
EA202091020A1 (en) SUBSTITUTED IMIDAZOPYRIDINAMIDES AND THEIR APPLICATION
SG11201809845TA (en) Benzodiazepine product with activity on the central nervous and vascular systems
MX2020001855A (en) Pharmaceutical compositions containing anti-beta amyloid antibodies.
MX2019000982A (en) Compounds and compositions and uses thereof.
EP3395804A4 (en) Novel spiroquinone derivative compound, production method thereof, and pharmaceutical composition for preventing or treating neurological disorders which contains same as active ingredient
MX2022005084A (en) Solid forms of an s1p-receptor modulator.
WO2017103892A3 (en) Composition for treating and preventing neurological diseases, neuroinflammation, and alzheimer's disease
MX2018003565A (en) 2,3,4,5-tetrahydropyridin-6-amine derivatives.
MX2020003844A (en) Compound and composition for use in the preventive and/or curative treatment of diseases of the central nervous system characterised by a decline in neuronal plasticity, in particular characterised by a decline in synaptic plasticity.
PH12020500233A1 (en) Adamantylmethylamine derivative and use thereof as pharmaceutical
IL288234A (en) Compounds for the treatment of neuromuscular disorders